Trafficking and proteolytic release of epidermal growth factor receptor ligands are modulated by their membrane-anchoring domains.
Ligands that bind to the epidermal growth factor (EGF) receptor are initially synthesized as integral membrane proteins that are released from the cell surface by regulated proteolysis. To study the role of the membrane-anchoring domain in ligand release, we made two artificial ligands. The first possessed the membrane-anchoring domain from EGF whereas the second had the corresponding domain from heparin binding EGF-like growth factor (HB-EGF). Both ligands lacked amino-terminal extensions, and were epitope-tagged at the carboxyl terminus. Following stable expression in human mammary epithelial cells, their cellular localization and rate of proteolytic release were examined. We found that constructs with the membrane-anchoring domain from EGF were found primarily at the cell surface and displayed a relatively high rate of constitutive release. Constructs with the HB-EGF membrane-anchoring domain displayed a higher internalized fraction and a very low rate of constitutive release. The two ligand constructs also displayed different patterns of stimulated release. Proteolysis of the chimera with the HB-EGF membrane-anchoring domain was stimulated by activation of protein kinase C, but release of EGF from constructs with the EGF membrane-anchoring domain was insensitive to this. Calcium ionophores, calmodulin antagonists, and tyrosine phosphatase inhibitors stimulated the release of both ligands. Furthermore, the release of the two constructs showed different sensitivity to metalloprotease inhibitors. Despite a large fold-increase in ligand proteolysis following cell stimulation, only a small fraction of total cell-associated ligand was released per hour. Our results show that the membrane-anchoring domain of EGF-like ligands can specify both their localization and proteolytic processing. The structures of the membrane-anchoring region of this class of ligands can thus regulate their activity.
Dong
J
J
Department of Pathology, Division of Cell Biology, University of Utah, Salt Lake City, Utah 84132, USA.
Wiley
H S
HS
D001692:Biological Transport; D000001:Calcimycin / Q000494:pharmacology; D004705:Endocytosis; D004815:Epidermal Growth Factor / Q000235:genetics / Q000378:metabolism*; D066246:ErbB Receptors / Q000378:metabolism*; D066257:Heparin-binding EGF-like Growth Factor; D006877:Hydroxamic Acids / Q000494:pharmacology; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors; D010446:Peptide Fragments / Q000235:genetics / Q000378:metabolism; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology
C088670:BB 2116; C587883:HBEGF protein, human; D066257:Heparin-binding EGF-like Growth Factor; D006877:Hydroxamic Acids; D036341:Intercellular Signaling Peptides and Proteins; D008024:Ligands; D010446:Peptide Fragments; D011994:Recombinant Proteins; D000001:Calcimycin; D004815:Epidermal Growth Factor; D066246:ErbB Receptors; D008666:Metalloendopeptidases; D013755:Tetradecanoylphorbol Acetate